NASDAQ:CABA 31 October 2025

Cabaletta Bio Stock Jumps: Inside the $150 Million Bet on CABA’s Cell Therapy

Shares of Cabaletta Bio Inc. surged roughly 32% late Monday, buoyed by news of early results from a small cell-therapy trial and the announcement of a $150 million stock sale that counted Eli Lilly among its participants. Trading hit $3.895 on strong volume, topping out intraday at $4.04, according to market data.

4 May 2026

Biotechnology·Healthcare Innovation·NASDAQ:CABA·NYSE:LLY·Stock Market

Cabaletta Bio stock jumps 11% premarket after insider buying cluster hits the tape

Cabaletta Bio shares climbed roughly 11% in premarket trading Thursday, following a nearly 7% gain the previous day, fueled by a series of insider-buying reports. The stock was last indicated at $2.60, up from Wednesday’s close of $2.34.

22 January 2026

NASDAQ:CABA·Stock Market

Biotech Boom: Cabaletta Bio’s CAR-T Trial Sparks 40% Stock Surge

Cabaletta’s stock has been very volatile. From ~$2.40 on Oct 27 it briefly dipped to the $2.47 area by Oct 30, then exploded higher on Oct 31. Benzinga notes that CABA “rose 36.6% to $3.38” intraday on Oct 31benzinga.com; it eventually closed at $3.61stockanalysis.com. Over the week of Oct 25–31, CABA gained ~37%tradingview.com. For perspective, its 52-week range is roughly $0.99–$5.46stockanalysis.com.

31 October 2025

Biotechnology·NASDAQ:CABA·Stock Market